Prognomics Ltd

PROGNOMICS is a high-tech start-up, dealing in sensing, diagnostics and monitoring technologies. Created in 2014 as a spin-out of Swansea University, we are developing next-gen portable solutions for early and rapid detection and diagnosis of disease onset, at the Point-of-Care, near-patient, and Point-of-Application (for non-health applications). Our novel patented platform technologies for electrochemical sensing applications offers rapid, high-sensitive and selective, low cost detection & monitoring. We are a highly focused R&D commercialisation vehicle and are advancing development of commercial prototypes utilising IP  covering generic biosensor, multiplexed biosensing and micro-droplet technologies. Partner in international high profile project, e.g., £1.25M EPSRC: “Novel Point-of-Care diagnostic techniques for Dementia” (EP/M006301/1), (next-gen graphene-based multiplexed biosensors for early detection of Dementia biomarkers). We are also a funded industrial partner in the €1bn, H2020 Graphene Flagship Consortium, to provide our core technology to develop highly selective graphene-based biosensors; Consortium Lead on InnovateUK (IUK) collaborative project with NPL and Cambridge University, and Work Package Lead in this MSCA project, BBDiag.